Merck Sharp + Dohme Corp.

Shanghai Huali Microelectronics Corporation

Msd R&d (china) Co., Ltd.

Msd R&d Co., Ltd.

Bin Zhong

Bin Hu

Craig Alan Coburn

Joseph A Kozlowski

Dahai Wang

Hao Wu

Wensheng Yu

Jinglai Hao

Michael P Dwyer

John A McCauley

Kun Liu

Ling Tong

Richard Soll

Kartik M Keertikar

Jian Zhu

Steven W Ludmerer

Tao Ji

Peter D Williams

Fei Sun

Sherman Tim Waddell

Gregori J Morriello

Xin-Jie Chu

M Katharine Holloway

Christopher James Bungard

Lehua Chang

David Jonathan Bennett

Catherine M Wiscount

H Marie Loughran

Jun Zhou

Joseph P Vacca

Stuart B Rosenblum

Lei Chen

Dong-Ming Shen

Bandarpalle B Shankar

Wei Wei

De-Yi Yang

Razia Rizvi

Nicolas Zorn

Deyou Sha

HaiFeng Zhou

Edward C Sherer

Oleg B Selyutin

Alejandro Crespo

Satyanarayana Tummanapalli

Xinghai Wang

Jae-Hun Kim

Jesse J Manikowski

Mingwei Zheng

Yu Bao

Changmao Shen

Vijayasaradhi Sivalenka

Richard Soil

Jurgen Schulz

Jessie J Manikowski

Jurgen Schultz

Xiaoqiang Zhou

Zhixin Lei

Man Yan

Chengren Zhang

John A Mccauley

M Katherine Holloway

Tummanapalli Satyanarayana

Sivalenka Vijayasaradhi

Shuai Zan

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Inhibitors of hepatitis C virus replication

A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject. 

Hepatitis C virus inhibitors

The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', RR, Rand Rare as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', RRand Rare as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. 

Piperazine derivatives as HIV protease inhibitors

The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A', R, R, R, R, R, and Rare defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient. 

Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases

A method of removing a dummy gate dielectric layer is provided. Firstly a first plasma containing F is utilized to remove the dummy dielectric layer which contains Si and O. Then a second plasma containing His utilized to remove fluorine compound on the surface of the semiconductor substrate. Since the fluorine residue formed after the first plasma treatment reacts with the second plasma to form a gaseous product HF, the fluorine element can be taken away from the semiconductor device with the HF, which prevents inversion layer offset and gate current leakage occurred in the subsequent processing steps due to the fluorine element.

Method of removing dummy gate dielectric layer

The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y, Y, Z, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient. 

Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases

Growing community of inventors

Shanghai, China

Bin Zhong